To The Moon

Tango Therapeutics Inc. (NASDAQ: TNGX) is a hidden gem in the biotech sector, and I’m here to make the case for why this stock is a screaming buy right now. Trading at just $3.24 as of June 4, 2025, TNGX has all the makings of a breakout candidate: a promising clinical pipeline, strong analyst support, a solid cash position, and recent catalysts that are starting to turn heads. If you’re a growth investor with an appetite for high-reward opportunities, this stock deserves a spot on your radar. Let’s dive into the reasons why I’m strongly bullish on TNGX.

A Precision Oncology Powerhouse with a Game-Changing Pipeline

Tango Therapeutics is a clinical-stage biotech company focused on precision oncology, specifically targeting cancers with MTAP deletions—a genetic feature found in a wide range of tumors like pancreatic cancer, lung cancer, and glioblastoma. The company’s lead programs, TNG462 and TNG456, are PRMT5 inhibitors designed to exploit this vulnerability, offering a novel approach to treating some of the deadliest cancers.

• TNG462 is in a Phase 1/2 trial for non-CNS cancers, with data updates expected in the second half of 2025. The company is also gearing up for a pivotal pancreatic cancer study in 2026, which could be a major value driver if successful.

• TNG456, a brain-penetrating PRMT5 inhibitor for CNS cancers like glioblastoma, just dosed its first patient in May 2025. This milestone is a big deal—glioblastoma is notoriously hard to treat, and a breakthrough here could position Tango as a leader in this space.

• On top of that, Tango is planning a combination trial in Q2 2025, pairing TNG462 with Revolution Medicines’ RAS(ON) inhibitors for pancreatic and lung cancer. Preclinical data has been promising, and this could open up even more opportunities.

The broader market is starting to take notice of PRMT5 inhibitors as a viable target. At ASCO 2025, Bristol Myers Squibb presented data showing durable responses in MTAP-deleted lung and pancreatic cancers, validating the approach Tango is taking. This third-party validation adds a layer of confidence to Tango’s pipeline and suggests that their programs could be game-changers.

Undervalued with Explosive Upside Potential

At $3.24, TNGX is trading near the lower end of its 52-week range ($1.03–$12.02), with a market cap of just $222 million. Yet, Wall Street analysts are pounding the table on this stock. The consensus 12-month price target is $11.22, implying a potential upside of over 246%. Some analysts are even more optimistic—Jefferies set a high target of $19 back in July 2024, while HC Wainwright recently pegged it at $13, suggesting a possible 300%+ rally.

This isn’t just blind optimism. Tango’s pipeline addresses high-unmet-need cancers, and success in their trials could lead to blockbuster potential. The stock’s current price doesn’t reflect the value of its assets, making it a classic undervalued biotech play with massive upside.

Financial Runway to Weather the Storm

One of the biggest risks with early-stage biotechs is running out of cash, but Tango is in a strong position here. As of March 31, 2025, the company had $216.7 million in cash and equivalents—enough to fund operations into Q1 2027. That gives them a two-year runway to hit key milestones without the immediate need for dilutive financing.

Yes, their Q1 2025 earnings showed a revenue dip to $5.39 million (down 16.7% year-over-year) and a net loss of $39.9 million (up 5.2%). But this isn’t unusual for a biotech in their stage—most of their spending is on R&D to push their pipeline forward. With no major debt and a clean balance sheet, Tango has the financial flexibility to execute on its plans.

Catalysts on the Horizon

Tango has a packed calendar of potential catalysts that could drive the stock higher in the near term:

• TNG462 data update in H2 2025 could provide proof of efficacy and safety, potentially sparking a rally.

• The TNG456 glioblastoma trial is now underway, and early data could be a major inflection point given the lack of effective treatments in this space.

• The combination trial with Revolution Medicines starting in Q2 2025 could further de-risk their pipeline and attract partnership interest.

Add to that the growing buzz around PRMT5 inhibitors—fueled by the ASCO 2025 data—and you have a recipe for significant market interest. Social media platforms like X are already lighting up with chatter about TNGX’s potential. One user, @Bezel4455, summed it up well: “Up 30% 🚀🧬 First patient dosed in PRMT5 glioblastoma trial 🎯 $216M cash = runway into 2027 💰 Analysts still pounding the table — $10+ targets 📈 Undervalued biotech with massive upside potential.”

Risks Are Real, But the Reward Is Worth It

No biotech investment is without risk. Tango’s stock is volatile—its 52-week range shows how quickly sentiment can shift. Clinical trial failures could tank the stock, especially if TNG462 or TNG456 data disappoints. Cash burn is another concern; while they’re funded into 2027, a prolonged trial delay or unexpected costs could force them to raise capital sooner, potentially diluting shareholders.

There’s also some mixed sentiment on X. Some users, like @AnExpertOne1, pointed out insider selling at lower prices and low options volume, which could signal caution: “Up a massive 33% w/ just barely over 2K Calls volume - also has had huge insider selling at lower prices, oddly.” But insider selling isn’t always a red flag—it could be personal financial planning rather than a lack of confidence—and the low options volume might simply reflect the stock’s under-the-radar status.

Despite these risks, the reward potential far outweighs the downside for me. Biotech stocks often see 100%+ moves on positive trial data, and Tango is well-positioned for that kind of run.

Why Now Is the Time to Buy

TNGX is at a pivotal moment. The stock has already shown signs of life, climbing 27.5% to $3.24 recently, yet it remains deeply undervalued compared to analyst targets. The combination of a validated scientific approach, a robust pipeline, upcoming catalysts, and a strong cash position makes this a compelling opportunity.

For investors who can stomach the volatility, TNGX offers a rare chance to get in on the ground floor of a potential biotech leader. If their PRMT5 inhibitors deliver in the clinic, this stock could easily triple—or more—within the next 12–18 months. Don’t wait for the crowd to catch on—this is the time to take a position in Tango Therapeutics.

Disclaimer: Investing in biotech stocks carries significant risks, including the potential for substantial losses. Always conduct your own research or consult with a financial advisor before making investment decisions.

Sources:

• Tango Therapeutics Q1 2025 Financial Results: Tango Therapeutics Investor Relations

• ASCO 2025 Data on PRMT5 Inhibitors: Bristol Myers Squibb News

• Analyst Price Targets: Benzinga

• Social Media Sentiment: X posts from @Bezel4455 and @AnExpertOne1